Reevaluation and Identification of the Best Immunohistochemical Panel (pVHL, Maspin, S100P, IMP-3) for Ductal Adenocarcinoma of the Pancreas
Reevaluation and Identification of the Best Immunohistochemical Panel (pVHL, Maspin, S100P, IMP-3) for Ductal Adenocarcinoma of the Pancreas
复制标题
DOI：
10.5858/arpa.2011-0326-oa
复制
发表时间：
2012-06-01
影响因子：
4.6
通讯作者：
Lin, Fan
中科院分区：
文献类型：
--
作者：
Liu, Haiyan;Shi, Jianhui;Lin, Fan
背景.-区分胰腺导管腺癌与非肿瘤性胰腺组织可能具有挑战性，特别是在小活检和细针抽吸标本中。目的.-研究 26 种免疫组织化学标记物（CAM 5.2、CK [细胞角蛋白] 7、CK20、CK17、CK19、MUC1、MUC2、 MUC4、MUC5AC、MUC6、p53、DPC4/SMAD4、CDX2、pVHL [von Hippel-Lindau 肿瘤抑制基因蛋白]、S100P、IMP-3 [胰岛素样生长因子 2 信使 RNA 结合蛋白 3]、maspin、间皮素、claudin 4、claudin 18、膜联蛋白 A8、肌成束蛋白、PSCA [前列腺干细胞抗原]、MOC31、CEA [癌胚抗原]和CA19-9 [癌抗原19-9])在胰腺导管腺癌诊断中的应用。设计。-对60例胰腺导管腺癌的常规和组织进行这些标记物的免疫组织化学染色 微阵列切片。此外，对 67 例胰腺细针抽吸病例（其中 44 例胰腺导管腺癌）的细胞块进行了 maspin、S100P、IMP-3 和 pVHL 的免疫组织化学染色。结果。-结果表明（1）90% 以上的导管腺癌病例中 maspin、S100P 和 pVHL 呈阳性。 IMP-3； (2)几乎所有腺癌病例的pVHL均为阴性，而非肿瘤性导管和腺泡的pVHL均呈阳性； (3) 正常/反应性胰管经常呈 CK7、CK19、MUC1、MUC6、CA19-9、MOC31、PSCA、间皮素、膜联蛋白 A8、紧密蛋白 4 和紧密蛋白 18 阳性； (4)正常胰管通常IMP-3、maspin、S100P、CK17、MUC2、MUC4和MUC5AC阴性； (5) 60%的腺癌DPC4/SMAD4呈阴性； (6) 肌成束蛋白、PSCA 和膜联蛋白 A8 经常出现强背景染色。结论。-pVHL、maspin、S100P 和 IMP-3 构成了手术和细针抽吸标本中胰腺导管腺癌诊断的最佳免疫标记物诊断组。 （Arch Pathol 实验室医学。2012 年；136：601-609；doi：10.5858/arpa.2011-0326-OA）
Context.-Differentiation of ductal adenocarcinoma of the pancreas from nonneoplastic pancreatic tissues can be challenging, especially in small biopsy and fine-needle aspiration specimens.Objective.-To investigate the utility of 26 immunohistochemical markers (CAM 5.2, CK [cytokeratin] 7, CK20, CK17, CK19, MUC1, MUC2, MUC4, MUC5AC, MUC6, p53, DPC4/SMAD4, CDX2, pVHL [von Hippel-Lindau tumor suppressor gene protein], S100P, IMP-3 [insulin-like growth factor 2 messenger RNA binding protein 3], maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA [prostate stem cell antigen], MOC31, CEA [carcinoembryonic antigen], and CA19-9 [cancer antigen 19-9]) in the diagnosis of ductal adenocarcinoma of the pancreas.Design.-Immunohistochemical staining for these markers was performed in 60 cases of pancreatic ductal adenocarcinoma on routine and tissue microarray sections. In addition, immunohistochemical staining for maspin, S100P, IMP-3, and pVHL was performed on cell blocks from 67 pancreatic fine-needle aspiration cases, including 44 cases of pancreatic ductal adenocarcinoma.Results.-The results demonstrated that (1) more than 90% of cases of ductal adenocarcinoma were positive for maspin, S100P, and IMP-3; (2) nearly all adenocarcinoma cases were negative for pVHL, whereas nonneoplastic ducts and acini were positive for pVHL in all cases; (3) normal/reactive pancreatic ducts were frequently positive for CK7, CK19, MUC1, MUC6, CA19-9, MOC31, PSCA, mesothelin, annexin A8, claudin 4, and claudin 18; (4) normal pancreatic ducts were usually negative for IMP-3, maspin, S100P, CK17, MUC2, MUC4, and MUC5AC; (5) 60% of adenocarcinomas were negative for DPC4/SMAD4; and (6) strong background staining was frequently seen with fascin, PSCA, and annexin A8.Conclusions.-pVHL, maspin, S100P, and IMP-3 constitute the best diagnostic panel of immunomarkers for confirming the diagnosis of pancreatic ductal adenocarcinoma in both surgical and fine-needle aspiration specimens. (Arch Pathol Lab Med. 2012;136:601-609; doi:10.5858/arpa.2011-0326-OA)